Contribution of intangible costs to the economic burden of multiple sclerosis

References

• Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343:938-952
   PubMed Web of Science ®Google Scholar
• Johansson S, Ytterberg C, Claesson IM, et al. High concurrent presence of disability in multiple sclerosis. Associations with perceived health. J Neurol 2007;254:767-773
   PubMed Web of Science ®Google Scholar
• Martin CL, Phillips BA, Kilpatrick TJ, et al. Gait and balance impairment in early multiple sclerosis in the absence of clinical disability. Mult Scler 2006;12:620-628
   PubMed Web of Science ®Google Scholar
• Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 2000;6:91-98
   PubMed Web of Science ®Google Scholar
• Patwardhan MB, Matchar DB, Samsa GP, et al. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler 2005;11:232-239
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis. A cross-sectional study in the United States. Neurology 2006;66:1696-1702
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;77:918-926
   PubMed Web of Science ®Google Scholar
• McCrone P, Heslin M, Knapp M, et al. Multiple sclerosis in the UK: service use, costs, quality of life and disability. Pharmacoeconomics 2008;26:847-860
   PubMed Web of Science ®Google Scholar
• Sobocki P, Pugliatti M, Lauer K, et al. Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult Scler 2007;13:1054-1064
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452
   PubMed Web of Science ®Google Scholar
• Kurtzke JF, Wallin MT. Epidemiology. In: Burks JS, Johnson KP, eds. Multiple Sclerosis: Diagnosis, Medical Management, and Rehabilitation. New York: Demos, 2000:49-71
   Google Scholar
• Sadovnick AD, Ebers GC, Wilson RW, et al. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992;42:991-994
   PubMed Web of Science ®Google Scholar
• Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995;13:119-146
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis: Hope Through Research. National Institute of Neurological Disorders and Stroke. Bethesda, MD. Updated April 28, 2010. Available at: www.ninds.nih.gov/disorders/multiple_sclerosis/detail_multiple_sclerosis.htm#153333215 [Last accessed 1 July 2010]
   Google Scholar
• Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-425
   PubMed Web of Science ®Google Scholar
• Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programmes, 2nd ed. Oxford: Oxford University Press, 1997
   Google Scholar
• Wu N, Minden SL, Hoaglin DC, et al. Quality of life in people with multiple sclerosis: data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. J Health Hum Serv Adm 2007;30:233-267
   PubMedGoogle Scholar
• Nortvedt MW, Riise T, Myhr KM, et al. Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology 1999;53:1098-1103
   PubMed Web of Science ®Google Scholar
• Solari A, Radice D. Health status of people with multiple sclerosis: a community mail survey. Neurol Sci 2001;22:307-315
   PubMed Web of Science ®Google Scholar
• Hemmett L, Holmes J, Barnes M, et al. What drives quality of life in multiple sclerosis? Q J Med 2004;97:671-676
   Google Scholar
• Nortvedt MW, Riise T. The use of quality of life measures in multiple sclerosis research. Mult Scler 2003;9:63-72
   PubMed Web of Science ®Google Scholar
• Jones CA, Pohar SL, Warren S, et al. The burden of multiple sclerosis: a community health survey. Health Qual Life Outcomes 2008;6:1
   PubMed Web of Science ®Google Scholar
• Casado V, Romero L, Giubieras L, et al. An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain. Mult Scler 2007;13:800-804
   PubMed Web of Science ®Google Scholar
• The EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, et al., eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press, 1996
   Google Scholar
• CHOosing Interventions that are Cost Effective (WHO-CHOICE). World Health Organization (WHO), Geneva, Switzerland, 2010. Available at: www.who.int/choice/costs/CER_thresholds/en/index.html [Last accessed 1 July 2010]
   Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in The Netherlands. Eur J Health Econ 2006;7:S55-64
   Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ 2006;7(Suppl 2):S45-54
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Austria. Eur J Health Econ 2006;7(Suppl 2):S14-23
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ 2006;7(Suppl 2):S34-44
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life for patients with multiple sclerosis in Belgium. Eur J Health Econ 2006;7(Suppl 2):S24-33
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Switzerland. Eur J Health Econ 2006;7(Suppl 2):S86-95
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ 2006;7(Suppl 2):S65-74
   PubMedGoogle Scholar
• Berg J, Lindgren P, Fredrikson S, et al. Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ 2006;7(Suppl 2):S75-85
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ 2006;7(Suppl 2):S96-104
   PubMedGoogle Scholar
• Henriksson F, Fredrikson S, Jonsson B. Costs, quality of life and disease severity in multiple sclerosis – a population-based cross-sectional study in Sweden. Stockholm: Stockholm School of Economics; 2000 SSE/EFI Working Paper Series in Economics and Finance, March. Report No. 361
   Google Scholar
• Henriksson F, Fredrikson S, Masterman T, et al. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol 2001;8:27-35
   PubMed Web of Science ®Google Scholar
• Kobelt G, Lindgren P, Parkin D, et al. Costs and quality of life in multiple sclerosis. a cross-sectional observational study in the UK. Stockholm: Stockholm School of Economics; 2000 SSE/EFI Working Paper Series in Economics and Finance. Report No. 398
   Google Scholar
• Naci H, Fleurence R, Birt J, et al. The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature. J Med Econ 2010;13:78-89
   PubMedGoogle Scholar
• Kind P, Hardman G, Macran S. UK Population norms for EQ-5D. Discussion Paper #172. University of York Centre for Health Economics, York, UK, 1999. Available at: www.york.ac.uk/inst/che/pdf/DP172.pdf [Last accessed 1 July 2010]
   Google Scholar
• Naci H, Fleurence R, Birt J, et al. Economic burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics 2010;28:363-379
   PubMed Web of Science ®Google Scholar
• Gyrd-Hansen D. Willingness to pay for a QALY: theoretical and methodological issues. Pharmacoeconomics 2005;23:423-432
   PubMed Web of Science ®Google Scholar
• King Jr JT, Tsevat J, Lave JR, et al. Willingness to pay for a quality-adjusted life-year: implications for societal health care resource allocation. Med Decis Making 2005;25:667-677
   PubMed Web of Science ®Google Scholar
• Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn’t it increase at the rate of inflation? [commentary]. Arch Intern Med 2003;163:1637-1641
   PubMed Web of Science ®Google Scholar
• Braithwaite RS, Meltzer DO, King JT Jr, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008;46:349-356
   PubMed Web of Science ®Google Scholar
• Lee CP, Chertow G, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health 2009;12:80-87
   PubMed Web of Science ®Google Scholar